FI970071A0 - Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä - Google Patents

Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä

Info

Publication number
FI970071A0
FI970071A0 FI970071A FI970071A FI970071A0 FI 970071 A0 FI970071 A0 FI 970071A0 FI 970071 A FI970071 A FI 970071A FI 970071 A FI970071 A FI 970071A FI 970071 A0 FI970071 A0 FI 970071A0
Authority
FI
Finland
Prior art keywords
nucleic acid
acid sequence
sequence encoding
isolated nucleic
tumor rejection
Prior art date
Application number
FI970071A
Other languages
English (en)
Swedish (sv)
Other versions
FI970071A (fi
Inventor
Vincent Brichard
Pel Aline Van
Pierre Coulie
Thierry Boon-Falleur
Plaen Etienne De
Catia Traversari
Thomas Wolfel
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of FI970071A publication Critical patent/FI970071A/fi
Publication of FI970071A0 publication Critical patent/FI970071A0/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
FI970071A 1994-07-08 1997-01-07 Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä FI970071A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27235194A 1994-07-08 1994-07-08
US08/370,319 US5856091A (en) 1993-03-18 1995-01-10 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
PCT/US1995/008153 WO1996001557A1 (en) 1994-07-08 1995-06-27 Isolated nucleic acid sequence coding for a tumor rejection antigen presented by hla-a2

Publications (2)

Publication Number Publication Date
FI970071A FI970071A (fi) 1997-01-07
FI970071A0 true FI970071A0 (fi) 1997-01-07

Family

ID=26955454

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970071A FI970071A0 (fi) 1994-07-08 1997-01-07 Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä

Country Status (10)

Country Link
US (2) US5856091A (fi)
EP (1) EP0772626A4 (fi)
JP (1) JPH10503928A (fi)
CN (1) CN1152251A (fi)
AU (1) AU696738B2 (fi)
CA (1) CA2194451A1 (fi)
FI (1) FI970071A0 (fi)
NO (1) NO970030D0 (fi)
NZ (1) NZ289616A (fi)
WO (1) WO1996001557A1 (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
EP0910646A1 (en) * 1996-06-25 1999-04-28 The Ludwig Institute for Cancer Research Brain glycogen phosphorylase cancer antigen
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
CN104662171B (zh) * 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
US10605766B2 (en) * 2014-07-15 2020-03-31 Illumina, Inc. Biochemically activated electronic device
US10987045B2 (en) 2015-09-14 2021-04-27 Biosense Webster (Israel) Ltd. Basket catheter with individual spine control

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297893A (en) 1963-09-19 1967-01-10 Litz Co Brush mechanisms
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
EP0772626A4 (en) 1997-09-10
AU2951795A (en) 1996-02-09
CN1152251A (zh) 1997-06-18
NO970030L (no) 1997-01-06
CA2194451A1 (en) 1996-01-25
NO970030D0 (no) 1997-01-06
EP0772626A1 (en) 1997-05-14
US6201111B1 (en) 2001-03-13
FI970071A (fi) 1997-01-07
US5856091A (en) 1999-01-05
NZ289616A (en) 1997-12-19
JPH10503928A (ja) 1998-04-14
WO1996001557A1 (en) 1996-01-25
AU696738B2 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
FI914908A0 (fi) Ny monoklonal antikropp med ny antigen relaterad till humana tumoerer.
NO880395L (no) Antigener.
DK296189D0 (da) Nucleinsyresekvenser, som koder for peptidsekvenser af carcinoembryonisk antigen-familien
DE69018801T2 (de) Chimärischer anti-cae-antikörper.
FI862761A0 (fi) Klonad antigen.
FI970071A0 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä
DK163062C (da) Antigen, immunogen, proteinholdig vaccine imod coccidiose
IT1198289B (it) Antigene di flavvirus
FI913787A0 (fi) Papiljott.
EP0910396A4 (en) ISOLATED NUCLEIC ACID MOLECULES ENCODING THE GAGE TUMOR REPELLENT REPELLENTANT, THE TUMOR REPELLENT REPELLENTANT AND ITS USE
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
FI861691A (fi) En ny tumoerassocierad antigen.
DE3768814D1 (de) Lockenwickler.
NO965087D0 (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
FI904890A0 (fi) Foerfarande och bruksfoerpackning foer bestaemning av herpes simplex-virus antigen genom direkt bindning till polymerpartiklar.
FI904357A0 (fi) Foerfarande foer aktivering av protein c.
DE68909203D1 (de) Gewickelte Feder.
DE3687542D1 (de) Monoklonaler antikoerper gegen humanes protein c.
FI891406A0 (fi) Patron.
NO885392D0 (no) Humant tumor-assosiert antigen.
NO901587L (no) Syntetisk dna-sekvens som koder for humaninsulinlignende vekstfaktor ii.
FI861576A0 (fi) Blekande kosmetika.
DK182188D0 (da) Humant tumorassocieret antigen
FI891618A0 (fi) Propp.
FI891619A0 (fi) Propp.